脂毒性,脂质过氧化和铁:癌症治疗中的困境
Chuhan Ma1, Huixin Hu1, Hao Liu1
1Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning Province, China.
Cell biology and toxicology
|April 26, 2025
概括
脂质过氧化和铁化会产生一种免疫抑制的瘤微环境. 他们的产品可以通过影响免疫细胞来阻碍基于铁亡的癌症疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞死亡研究 细胞死亡研究
背景情况:
- 瘤细胞易受脂质过氧化的影响,原因是瘤微环境 (TME) 中的氧化还原失衡和脂质积累.
- 脂质过氧化驱动的细胞死亡形式铁亡,是新的抗癌策略的关键目标.
- 脂质过氧化产品,如4-hydroxynonenal (HNE),可以破坏DNA并促进瘤生长,转移和免疫抑制.
研究的目的:
- 审查脂质过氧化产品和铁化在制造免疫抑制性TME中的协同机制.
- 要突出这些过程如何影响各种免疫细胞,包括巨细胞,树突细胞,T细胞,NK细胞和中性粒细胞.
- 强调脂质过氧化产品阻碍ferroptosis治疗的临床应用的潜力.
主要方法:
- 文献综述侧重于脂质过氧化,铁和瘤免疫微环境之间的相互作用.
- 分析脂质过氧化产品对免疫细胞功能和表型的影响.
- 检查现有的纳米疗法及其在解决脂质过氧化效应方面的局限性.
主要成果:
- 脂质过氧化和铁致死会在TME内诱导一个暂时不同的免疫抑制状态.
- 这些过程会对抗原呈现,细胞毒性功能产生负面影响,并促进原瘤性免疫细胞表型 (例如,PMN-MDSC).
- 斯特罗马细胞脂质过氧化也会导致整体瘤进展和免疫逃避.
结论:
- 了解脂质过氧化产品的免疫抑制作用对于有效的基于铁灭的癌症治疗至关重要.
- 需要进一步的研究,以探索可以抵消TME中脂质过氧化的免疫抑制作用的策略.
- 解决这些机制可以提高ferroptosis诱导的抗瘤策略的临床翻译和疗效.
相关概念视频
01:16Necrosis
3.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
3.6K
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:46Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
02:53Adaptive Mechanisms in Cancer Cells
5.5K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.5K